Scorr-Insert
X

Find Novel Drugs for Infections and Infectious Diseases under Development in CHINA

A collaboration with SCORR Marketing

Loading...

All Data

Filters Filter refresh
×
FILTER DATA :
News Type filter
    Company filter
      Product Type filter
        Deal Size filter
          Upfront Payment filter
            refresh

            Product Type Full Screen

            Companies Full Screen

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Antibody drug conjugate

            Therapeutic Area: Infections and Infectious Diseases

            Highest Development Status: Undisclosed Product Type: Large molecule

            Partner/Sponsor/Collaborator: Shanghai Henlius Biotech

            Deal Size: $3.5 million Upfront Cash: Undisclosed

            Deal Type: Agreement May 06, 2020

            Details:

            Agreement aims to develop fully human antibody drug for covid-19 for monotherapy or combination treatment of covid-19.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): JS016

            Therapeutic Area: Infections and Infectious Diseases

            Highest Development Status: Undisclosed Product Type: Large molecule

            Partner/Sponsor/Collaborator: Eli Lilly

            Deal Size: Undisclosed Upfront Cash: Undisclosed

            Deal Type: Agreement May 04, 2020

            Details:

            Junshi Biosciences and Lilly aim to submit an IND application and initiate clinical studies in the U.S. in the second quarter of the year.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Recombinant proteins

            Therapeutic Area: Infections and Infectious Diseases

            Highest Development Status: Undisclosed Product Type: Large molecule

            Partner/Sponsor/Collaborator: GeoVax Labs

            Deal Size: Undisclosed Upfront Cash: Undisclosed

            Deal Type: Licensing Agreement April 30, 2020

            Details:

            Sino Biological will provide key bioreagents such as recombinant proteins, antibodies and detection kits for use in COVID-19 vaccine development underway at GeoVax.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Zanubrutinib

            Therapeutic Area: Infections and Infectious Diseases

            Highest Development Status: Undisclosed Product Type: Small molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable April 16, 2020

            Details:

            BeiGene has submitted a phase-2 randomized trial to the Food and Drug Administration that plans to enroll 42 U.S. patients.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): ACE-MAB

            Therapeutic Area: Infections and Infectious Diseases

            Highest Development Status: Undisclosed Product Type: Large molecule

            Partner/Sponsor/Collaborator: Sorrento Therapeutics

            Deal Size: Undisclosed Upfront Cash: Undisclosed

            Deal Type: Licensing Agreement March 24, 2020

            Details:

            Sorrento has been granted an exclusive license to develop and commercialize the ACE-MAB product candidate in the North American and European markets.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Favipiravir

            Therapeutic Area: Infections and Infectious Diseases

            Highest Development Status: Undisclosed Product Type: Small molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable March 19, 2020

            Details:

            Favipiravir alleviated the pneumonia symptom of COVID-19 patients with high tolerance and few adverse reactions, potentially through a mechanism that can quickly eliminate the coronaviruses.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Favipiravir

            Therapeutic Area: Infections and Infectious Diseases

            Highest Development Status: Undisclosed Product Type: Small molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable March 02, 2020

            Details:

            The Trials are random, parallel dose exploration studies with three dosage groups (high, middle and low dosage) to explore the best treatment regimen of Favipiravir for COVID-19 patients.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Human monoclonal antibodies

            Therapeutic Area: Infections and Infectious Diseases

            Highest Development Status: Undisclosed Product Type: Large molecule

            Partner/Sponsor/Collaborator: Vir Biotechnology

            Deal Size: Undisclosed Upfront Cash: Undisclosed

            Deal Type: Collaboration February 25, 2020

            Details:

            Under the terms of the agreement, the companies will work together on the clinical development, manufacturing, and commercialization of Vir's proprietary antibodies.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Favipiravir

            Therapeutic Area: Infections and Infectious Diseases

            Highest Development Status: Undisclosed Product Type: Small molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable February 18, 2020

            Details:

            Fapilavir allegedly demonstrated efficacy with minor side effects in an ongoing 70-patient clinical trial in Shenzhen, Guangdong province. The drug’s generic version received the approval.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): S-Trimer

            Therapeutic Area: Infections and Infectious Diseases

            Highest Development Status: Undisclosed Product Type: Vaccine

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable February 10, 2020

            Details:

            Clover is the first company in the world to disclose a 2019-nCoV vaccine candidate that can successfully be recognized by antibodies produced by previously-infected patients.

            PharmaCompass